EUIPO rules on Greek vitamin D trademark dispute

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

EUIPO rules on Greek vitamin D trademark dispute

Sponsored by

patrinos-logo.png
sunflower-1127174-1280.jpg

Maria Kilimiris of Patrinos & Kilimiris considers how the EUIPO and Greek courts decided on a trademark dispute on the content of pharma goods

Α Greek cosmetic and pharmaceutical company filed a European trademark (EUTM) application ‘Frezyderm Sunscreen Vitamin D-Like’ and device for ‘sun tanning and sun care preparations’ in class 03.

An application for cancellation due to invalidity based on absolute grounds was filed before EUIPO against the above EUTM, by a Greek company also active in the pharmaceutical and cosmetic field. The adversary claimed that the EUTM should be declared invalid as it has been registered in such a way that it deceives the public as to the nature or quality of the goods covered. 

In particular, the adversary claimed that the phrase ‘Vitamin D-Like’ directly refers to vitamin D, although the products covered by the trademark do not contain such vitamin. Instead, the basic ingredient used for their manufacture is the white peo D, which is not a vitamin. Moreover, the adversary claimed that it is not clear that there is no vitamin D in this product and that the average Greek consumer cannot realise the meaning of the phrase ‘Vitamin D-Like’.

In addition to the above invalidity action, the adversary had also filed, before the Greek National Organisation for Medicines (EOF), a complaint on a similar basis against the products at issue, as well as a preliminary injunction action before the Greek courts. The adversary’s complaint filed before EOF was rejected and it was decided that the phrase ‘Vitamin-D like skin benefits’ was not misleading and that the adversary’s allegation to the contrary should be rejected.

Regarding the ingredient of white peo D, which is the main substance of the products covered by the contested EUTM, the adversary claimed that this substance does not have the same beneficial effects as vitamin D, whereas the EUTM proprietor claimed the opposite. Both sides submitted scientific articles or expert opinions to support their above arguments.

EUIPO’s Cancellation Division dismissed the above argument raised by the adversary, ruling that this was irrelevant within the framework of Article 59(1)(a) EUTMR in conjunction with Article 7(1)(g) EUTMR because the list of goods does not contain a reference to white peo D.

Furthermore, the Cancellation Division ruled that the part of the relevant English-speaking public will understand the expression ‘Vitamin D-Like’ to mean that the contested products do not contain vitamin D, but rather a substitute. In addition, it was ruled that the list of goods covered by the contested trademark is broad so as to include all types of sun care products containing and non-containing Vitamin D or a substitute. 

In such a case it was ruled that, when broad categories of goods are registered and use of the mark could be deceptive for only some of the goods within the categories but not for other goods within the same categories, the mark as such is not considered to be deceptive and it is in general assumed that the mark will be used in a non-deceptive manner.

Patrinos & Kilimiris acted on behalf of the proprietor of the contested EUTM.

 

 

Maria Kilimiris

Partner, Patrinos & Kilimiris

E: info@patrinoskilimiris.com

 

more from across site and SHARED ros bottom lb

More from across our site

A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
Gift this article